Correspondence 0001104659-23-099611 from Bio Green Med Solution, Inc. (BGMS)
Bio Green Med Solution, Inc.
Date: Sept. 11, 2023 · CIK: 0001130166 · Accession: 0001104659-23-099611
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274328
Letter
CYCLACEL PHARMACEUTICALS, INC.
200 Connell Drive, Suite
Berkeley Heights, NJ 07922
VIA EDGAR
September 11, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed on September 1, 2023
File No. 333-274328
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. hereby requests that the effective date and time of the above-captioned registration statement be accelerated to Wednesday, September 13, 2023, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.
If you have any questions regarding this request, please contact Joel Papernik of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. at (212) 692-6774.
Thank you very much.
Very truly yours,
CYCLACEL PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CYCLACEL PHARMACEUTICALS, INC. 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 VIA EDGAR September 11, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed on September 1, 2023 File No. 333-274328 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. hereby requests that the effective date and time of the above-captioned registration statement be accelerated to Wednesday, September 13, 2023, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. If you have any questions regarding this request, please contact Joel Papernik of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. at (212) 692-6774. Thank you very much. Very truly yours, CYCLACEL PHARMACEUTICALS, INC. /s/ Paul McBarron Paul McBarron Chief Financial Officer cc: Securities and Exchange Commission Tyler Howes Cyclacel Pharmaceuticals, Inc. Spiro Rombotis, Chief Executive Officer Paul McBarron, Chief Financial Officer Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Joel Papernik, Esq.